Xenon Pharmaceuticals Inc. (XENE)


+0.14 (+0.36%)
Symbol XENE
Price $39.1
Beta 1.410
Volume Avg. 0.38M
Market Cap 2.485B
Shares () -
52 Week Range 26.25-43.57
1y Target Est -
DCF Unlevered XENE DCF ->
DCF Levered XENE LDCF ->
ROE -17.48% Sell
ROA -11.68% Sell
Operating Margin -
Debt / Equity 4.53% Neutral
P/E -16.57 Strong Sell
P/B 0 Neutral


Consensus EPS

Upgrades & Downgrades

Latest XENE news

Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA
NASDAQ Global Market

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.